Table 1 Efficacy of all the treatments regimens in network meta-analysis (pooled HR with 95%CI).

From: A network meta-analysis for neoadjuvant and adjuvant treatments for resectable squamous cell carcinoma of esophagus

neoCRT

1.48

(1.06,2.06)

1.84

(1.38,2.44)

2.30

(1.37,3.85)

1.17

(0.79,1.73)

1.63

(0.86,3.12)

0.68

(0.48,0.94)

neoRT

1.24

(0.83,1.86)

1.56

(0.91,2.65)

0.79

(0.50,1.24)

1.11

(0.54,2.25)

0.54

(0.41,0.73)

0.81

(0.54,1.20)

aCT

1.25

(0.73,2.14)

0.64

(0.40,1.02)

0.89

(0.46,1.72)

0.43

(0.26,0.73)

0.64

(0.38,1.09)

0.80

(0.47,1.36)

S

0.51

(0.27,0.95)

0.71

(0.32,1.59)

0.86

(0.58,1.27)

1.27

(0.81,1.98)

1.57

(0.98,2.52)

1.97

(1.05,3.68)

aCRT

1.40

(0.69,2.83)

0.61

(0.32,1.17)

0.90

(0.45,1.84)

1.12

(0.58,2.17)

1.41

(0.63,3.15)

0.71

(0.35,1.44)

neoCT

Back to article page